Valent P, Horny HP, Escribano L et al.. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603–625.
Swerdlow SH, Campo E, Harris NL et al.. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). International Agency for Research on Cancer; Lyon, France; 2017.
Ryan RJ, Akin C, Castells M et al.. Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol 2013;26:533–543.
Jawhar M, Schwaab J, Horny HP et al.. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Invest 2016;46:392–397.
Sanchez-Munoz L, Morgado JM, Alvarez-Twose I et al.. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br J Haematol 2016;172:56–63.
Nagata H, Worobec AS, Oh CK et al.. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92:10560–10564.
- Search Google Scholar
- Export Citation
. Nagata H Worobec AS Oh CK Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995; 92: 10560– 10564.
Schwaab J, Schnittger S, Sotlar K et al.. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013;122:2460–2466.
Hartmann K, Escribano L, Grattan C et al.. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016;137:35–45.
- Search Google Scholar
- Export Citation
. Hartmann K Escribano L Grattan C Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016; 137: 35– 45.
Escribano L, Alvarez-Twose I, Sanchez-Munoz L et al.. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514–521.
Lim KH, Tefferi A, Lasho TL et al.. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727–5736.
Pardanani A, Lim KH, Lasho TL et al.. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010;115:150–151.
Alvarez-Twose I, Jara-Acevedo M, Morgado JM et al.. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol 2016;137:168–178 e161.
Akin C, Scott LM, Kocabas CN et al.. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood 2007;110:2331–2333.
Pardanani A, Chen D, Abdelrahman RA et al.. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia 2013;27:2091–2094.
Lyons JJ, Yu X, Hughes JD et al.. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016;48:1564–1569.
Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226–232.
van Anrooij B, Kluin-Nelemans JC, Safy M et al.. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy 2016;71:1585–1593.
Gulen T, Hagglund H, Dahlen B, Nilsson G. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. J Intern Med 2016;279:211–228.
Zanotti R, Bonadonna P, Bonifacio M et al.. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica 2011;96:482–484.
Pardanani A, Lim KH, Lasho TL et al.. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009;114:3769–3772.
Wang SA, Hutchinson L, Tang G et al.. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol 2013;88:219–224.
Valent P, Sotlar K, Sperr WR et al.. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol 2014;25:1691–1700.
Valent P, Berger J, Cerny-Reiterer S et al.. Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Ann Hematol 2015;94:223–231.
Valent P, Sotlar K, Sperr WR et al.. Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. Leuk Res 2015;39:1–5.
Jawhar M, Schwaab J, Meggendorfer M et al.. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica 2017;102:1035–1043.
Sperr WR, Jordan JH, Fiegl M et al.. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002;128:136–141.
Schwartz LB, Metcalfe DD, Miller JS et al.. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987;316:1622–1626.
Sperr WR, El-Samahi A, Kundi M et al.. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009;39:914–923.
Aberer E, Savic S, Bretterklieber A et al.. Disease spectrum in patients with elevated serum tryptase levels. Australas J Dermatol 2015;56:7–13.
Horny HP, Sotlar K, Valent P. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology 2010;77:169–180.
Butterfield JH, Li CY. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? Am J Clin Pathol 2004;121:264–267.
Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC et al.. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011;24:1157–1168.
Reichard KK, Chen D, Pardanani A et al.. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. Am J Clin Pathol 2015;144:493–502.
Jordan JH, Walchshofer S, Jurecka W et al.. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001;32:545–552.
Horny HP, Sotlar K, Valent P. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells. Immunol Allergy Clin North Am 2014;34:315–321.
Teodosio C, Mayado A, Sanchez-Munoz L et al.. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. J Leukoc Biol 2015;97:49–59.
Escribano L, Diaz Agustin B, Bravo P et al.. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults. Leuk Lymphoma 1999;35:227–235.
Sotlar K, Horny HP, Simonitsch I et al.. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319–1325.
- Search Google Scholar
- Export Citation
. Sotlar K Horny HP Simonitsch I CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004; 28: 1319– 1325.
Pardanani A, Kimlinger T, Reeder T et al.. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004;28:777–783.
Morgado JM, Sanchez-Munoz L, Teodosio CG et al.. Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive’ alone is more informative than the ‘CD25 and/or CD2’ WHO criterion. Mod Pathol 2012;25:516–521.
Chisholm KM, Merker JD, Gotlib JR et al.. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am J Clin Pathol 2015;143:527–534.
Sotlar K, Cerny-Reiterer S, Petat-Dutter K et al.. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 2011;24:585–595.
Valent P, Sotlar K, Horny HP. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma 2011;52:740–744.
Morgado JM, Perbellini O, Johnson RC et al.. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology 2013;63:780–787.
Russano de Paiva Silva G, Tournier E, Sarian LO et al.. Prevalence of CD30 immunostaining in neoplastic mast cells: a retrospective immunohistochemical study. Medicine (Baltimore) 2018;97:e10642.
Mayado A, Teodosio C, Dasilva-Freire N et al.. Characterization of CD34(+) hematopoietic cells in systemic mastocytosis: potential role in disease dissemination. Allergy 2018;73:1294–1304.
Escribano L, Garcia Montero AC, Nunez R et al.. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am 2006;26:535–547.
Sanchez-Munoz L, Teodosio C, Morgado JM et al.. Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool. Immunol Allergy Clin North Am 2014;34:297–313.
Longley BJ, Tyrrell L, Lu SZ et al.. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312–314.
Garcia-Montero AC, Jara-Acevedo M, Teodosio C et al.. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366–2372.
- Search Google Scholar
- Export Citation
. Garcia-Montero AC Jara-Acevedo M Teodosio C KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366– 2372.
Sotlar K, Colak S, Bache A et al.. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010;220:586–595.
Tefferi A, Levine RL, Lim KH et al.. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009;23:900–904.
Traina F, Visconte V, Jankowska AM et al.. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One 2012;7:e43090.
Damaj G, Joris M, Chandesris O et al.. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One 2014;9:e85362.
Jawhar M, Schwaab J, Hausmann D et al.. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia 2016;30:2342–2350.
Jawhar M, Schwaab J, Schnittger S et al.. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia 2016;30:136–143.
Pardanani AD, Lasho TL, Finke C et al.. ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. Br J Haematol 2016;175:534–536.
Pardanani A, Lasho T, Elala Y et al.. Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol 2016;91:888–893.
Pardanani A, Ketterling RP, Brockman SR et al.. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093–3096.
Pardanani A, Brockman SR, Paternoster SF et al.. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104:3038–3045.
Bohm A, Fodinger M, Wimazal F et al.. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol 2007;120:192–199.
Arock M, Sotlar K, Akin C et al.. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia 2015;29:1223–1232.
Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011;13:180–188.
Kristensen T, Vestergaard H, Bindslev-Jensen C et al.. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014;89:493–498.
Jara-Acevedo M, Teodosio C, Sanchez-Munoz L et al.. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol 2015;28:1138–1149.
Kristensen T, Vestergaard H, Bindslev-Jensen C et al.. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis. Allergy 2017;72:1737–1743.
Sotlar K, Escribano L, Landt O et al.. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003;162:737–746.
Gotlib J, Pardanani A, Akin C et al.. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013;121:2393–2401.
- Search Google Scholar
- Export Citation
. Gotlib J Pardanani A Akin C International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013; 121: 2393– 2401.
Barete S, Assous N, de Gennes C et al.. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010;69:1838–1841.
Rossini M, Zanotti R, Bonadonna P et al.. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011;49:880–885.
van der Veer E, van der Goot W, de Monchy JG et al.. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012;67:431–438.
Metcalfe DD, Pawankar R, Ackerman SJ et al.. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J 2016;9:7.
Morrow JD, Guzzo C, Lazarus G et al.. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol 1995;104:937–940.
Oranje AP, Mulder PG, Heide R et al.. Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis. Clin Exp Dermatol 2002;27:502–506.
Butterfield JH. Increased leukotriene E4 excretion in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2010;92:73–76.
van Doormaal JJ, van der Veer E, van Voorst Vader PC et al.. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. Allergy 2012;67:683–690.
Divekar R, Butterfield J. Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders. Allergy 2015;70:1230–1238.
Cho C, Nguyen A, Bryant KJ et al.. Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. Immun Inflamm Dis 2016;4:64–69.
Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha. J Allergy Clin Immunol Pract 2014;2:775–778.
Cardet JC, Akin C, Lee MJ. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 2013;14:2033–2045.
Soter NA, Austen KF, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 1979;301:465–469.
Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990;85:852–855.
Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004;350:735–736.
Turner PJ, Kemp AS, Rogers M, Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 2012;29:222–223.
Butterfield JH. Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2009;88:122–124.
Broesby-Olsen S, Vestergaard H, Mortz CG et al.. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations. Allergy 2018;73:230–238.
Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R et al.. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007;37:1547–1555.
- Search Google Scholar
- Export Citation
. Gonzalez de Olano D de la Hoz Caballer B Nunez Lopez R Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007; 37: 1547– 1555.
Gulen T, Hagglund H, Dahlen B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis—a single-centre experience. Clin Exp Allergy 2014;44:121–129.
Gorska A, Niedoszytko M, Lange M et al.. Risk factors for anaphylaxis in patients with mastocytosis. Pol Arch Med Wewn 2015;125:46–53.
Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D et al.. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol 2014;133:520–528.
Gulen T, Ljung C, Nilsson G, Akin C. Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis. J Allergy Clin Immunol Pract 2017;5:1248–1255.
Niedoszytko M, Bonadonna P, Oude Elberink JN, Golden DB. Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients. Immunol Allergy Clin North Am 2014;34:365–381.
Jimenez-Rodriguez TW, Garcia-Neuer M, Alenazy LA, Castells M. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. J Asthma Allergy 2018;11:121–142.
Valent P. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy 2014;44:914–920.
van Anrooij B, van der Veer E, de Monchy JG et al.. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol 2013;132:125–130.
Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003;33:1216–1220.
Bonadonna P, Perbellini O, Passalacqua G et al.. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123:680–686.
Rueff F, Przybilla B, Bilo MB et al.. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009;124:1047–1054.
- Search Google Scholar
- Export Citation
. Rueff F Przybilla B Bilo MB Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124: 1047– 1054.
Alvarez-Twose I, Bonadonna P, Matito A et al.. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol 2013;131:614–615.
Castells MC, Hornick JL, Akin C. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? J Allergy Clin Immunol Pract 2015;3:350–355.
Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI et al.. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008;121:519–526.
Bonadonna P, Gonzalez-de-Olano D, Zanotti R et al.. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract 2013;1:474–478.
Verburg M, Oldhoff JM, Klemans RJ et al.. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis. Eur Ann Allergy Clin Immunol 2015;47:192–196.
Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:1027–1032.
Carter MC, Robyn JA, Bressler PB et al.. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007;119:1550–1551.
Rossini M, Zanotti R, Orsolini G et al.. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int 2016;27:2411–2421.
Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997;36:393–396.
Rossini M, Zanotti R, Viapiana O et al.. Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 2014;127:1127 e1121–1124.
Lehmann T, Beyeler C, Lammle B et al.. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol 1996;35:898–900.
Weide R, Ehlenz K, Lorenz W et al.. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 1996;72:41–43.
Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011;124:776–778.
Orsolini G, Gavioli I, Tripi G et al.. Denosumab for the treatment of mastocytosis-related osteoporosis: a case series. Calcif Tissue Int 2017;100:595–598.
Kruger A, Hamann C, Brendel C et al.. Multimodal therapy for vertebral involvement of systemic mastocytosis. Spine (Phila Pa 1976) 2009;34:E626–628.
Gotlib J, Kluin-Nelemans HC, George TI et al.. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 2016;374:2530–2541.
DeAngelo DJ, George TI, Linder A et al.. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia 2018;32:470–478.
Jawhar M, Schwaab J, Naumann N et al.. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood 2017;130:137–145.
Lim KH, Pardanani A, Butterfield JH et al.. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009;84:790–794.
- Search Google Scholar
- Export Citation
. Lim KH Pardanani A Butterfield JH Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009; 84: 790– 794.
Barete S, Lortholary O, Damaj G et al.. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood 2015;126:1009–1016.
Delaporte E, Pierard E, Wolthers BG et al.. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol 1995;132:479–482.
Casassus P, Caillat-Vigneron N, Martin A et al.. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002;119:1090–1097.
Hauswirth AW, Simonitsch-Klupp I, Uffmann M et al.. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004;28:249–257.
Simon J, Lortholary O, Caillat-Vigneron N et al.. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris) 2004;52:294–299.
Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115–1124.
Akin C, Brockow K, D'Ambrosio C et al.. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686–692.
Akin C, Fumo G, Yavuz AS et al.. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222–3225.
Zhang LY, Smith ML, Schultheis B et al.. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373–378.
Heinrich MC, Joensuu H, Demetri GD et al.. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717–2725.
Vega-Ruiz A, Cortes JE, Sever M et al.. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009;33:1481–1484.
Mital A, Piskorz A, Lewandowski K et al.. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011;86:531–535.
Alvarez-Twose I, Matito A, Morgado JM et al.. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget 2017;8:68950–68963.
Przepiorka D, Giralt S, Khouri I et al.. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998;57:24–28.
Nakamura R, Chakrabarti S, Akin C et al.. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006;37:353–358.
Ustun C, Reiter A, Scott BL et al.. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014;32:3264–3274.
Ustun C, Gotlib J, Popat U et al.. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transplant 2016;22:1348–1356.
Valent P, Akin C, Sperr WR et al.. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003;27:635–641.
Matito A, Morgado JM, Alvarez-Twose I et al.. Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One 2013;8:e76116.
Erben P, Schwaab J, Metzgeroth G et al.. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014;93:81–88.
Hoermann G, Gleixner KV, Dinu GE et al.. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy 2014;69:810–813.
Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 2013;121:3085–3094.
Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. Anesthesiology 2014;120:753–759.
Hermans MAW, Arends NJT, Gerth van Wijk R et al.. Management around invasive procedures in mastocytosis: an update. Ann Allergy Asthma Immunol 2017;119:304–309.
Matito A, Morgado JM, Sanchez-Lopez P et al.. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol 2015;167:47–56.
Guyer AC, Saff RR, Conroy M et al.. Comprehensive allergy evaluation is useful in the subsequent care of patients with drug hypersensitivity reactions during anesthesia. J Allergy Clin Immunol Pract 2015;3:94–100.
Woidacki K, Zenclussen AC, Siebenhaar F. Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome? Front Immunol 2014;5:231.
Ciach K, Niedoszytko M, Abacjew-Chmylko A et al.. Pregnancy and delivery in patients with mastocytosis treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM). PLoS One 2016;11:e0146924.
Matito A, Alvarez-Twose I, Morgado JM et al.. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases. Int Arch Allergy Immunol 2011;156:104–111.
Ulbrich F, Engelstadter H, Wittau N, Steinmann D. Anaesthetic management of emergency caesarean section in a parturient with systemic mastocytosis. Int J Obstet Anesth 2013;22:243–246.
Lei D, Akin C, Kovalszki A. Management of mastocytosis in pregnancy: a review. J Allergy Clin Immunol Pract 2017;5:1217–1223.